## **Summary**

Name Fc gamma RIIIA/CD16a/FCGR3A (V176)

**Purity** Greater than 95% as determined by reducing SDS-PAGE

**Endotoxin level** <1 EU/μg as determined by LAL test.

Construction Recombinant Human Fc Gamma RIIIA (V176) is produced by our Mammalian

expression system and the target gene encoding Gly17-Gln208 is expressed with a 6His tag at the C-terminus. It is identical to FCGR3A158F/V in the

reference.

Accession # AAH17865.1

**Host** Human Cells

**Species** Human

Predicted Molecular Mass 22.68 KDa

Formulation Lyophilized from a 0.2 µm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.

Shipping The product is shipped at ambient temperature. Upon receipt, store it

immediately at the temperature listed below.

**Stability&Storage** Store at  $\leq$ -70°C, stable for 6 months after receipt. Store at  $\leq$ -70°C, stable for 3


months under sterile conditions after opening. Please minimize freeze-thaw

cycles.

**Reconstitution** Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is

not recommended to reconstitute to a concentration less than 100µg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100µg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

### **SDS-PAGE** image



# **Background**

# Product Name: Recombinant Human CD16a (V176,C-6His) Enkilife Catalog #: PHH0301

**Alternative Names** 

Background

Low Affinity Immunoglobulin Gamma Fc Region Receptor III-A; CD16a Antigen; Fc-Gamma RIII-Alpha; Fc-Gamma RIII; Fc-gamma RIIIa; FcRIII; FcRIIIa; FcR-10; IgG Fc Receptor III-2; CD16a; FCGR3A; CD16A; FCGR3; FCGR3; IGFR3

Receptors for the Fc region of immunoglobin G (FcyR) are divided into three classes and FcyRIII is a multifunctional, low/intermediate affinity receptor. In humans, FcyRIII is expressed as two distinct forms (FcyRIIIA and FcyRIIIB) that are encoded by two different but highly homologous genes in a cell type-specific manner. FcyRIIIB is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas FcyRIIIA is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed by a subset of T lymphocytes, natural killer (NK) cells, monocytes, and macrophages. The FcyRIIIA receptor is involved in phagocytosis, secretion of enzymes, inflammatory mediators, antibody-dependent cellular cytotoxicity (ADCC), mast cell degranulation, and clearance of immune complexes. FcyRIIIA has an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain and delivers an activation signal in the immune responses. Aberrant expression or mutations in this gene is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia. In humans, it is a 50 -70 kD type I transmembrane activating receptor. The FcyRIIIA cDNA encodes 254 amino acid including a 16aa signal sequence, 191 amino acid ECD with two C2-type Ig-like domains, five potential N-glycosylation sites, a 22 amino acid transmembrane sequence and a 25 amino acid cytoplasmic domain.

#### Note

For Research Use Only, Not for Diagnostic Use.

Web: https://www.enkilife.com E-mail: order@enkilife.com techsupport@enkilife.com Tel: 0086-27-87002838